Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT6A | Q92794 | 3/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.44 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 3/20 | 0.41 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.41 |
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.40 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.40 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4073629 | 0.81 | MMP2 (0.50) | CYP3A4 | |
| SCHEMBL14572884 | 0.81 | KDM2B (0.48) | KAT6AHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL4078410 | 0.80 | HSD11B1 (0.50) | — | |
| SCHEMBL2376992 | 0.80 | SLC40A1 (0.45) | KAT6AHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL4079385 | 0.79 | KAT6A (0.38) | KAT6AHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL8429719 | 0.77 | CA1 (0.51) | HDAC3HDAC11HDAC8HDAC6CYP3A4 | |
| SCHEMBL14488990 | 0.75 | CYP1A2 (0.52) | KAT6AHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL9870257 | 0.75 | KAT6A (0.46) | KAT6AHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL2320239 | 0.74 | CA12 (0.42) | KAT6AHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL8075337 | 0.74 | CA2 (0.55) | KAT6ASLC40A1PTGES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1625112-B1 | NOVEL COMPOUNDS FOR TREATMENT OF OBESITY | HIGH POINT PHARMACEUTICALS LLC (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20060128662-A1 | Novel compounds for treatment of obesity | NOVO NORDISK A/S (DK) | 2006-06-15 | — | — | US | disclosed |
| EP-1625112-A1 | NOVEL COMPOUNDS FOR TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2006-02-15 | — | — | EP | disclosed |
| WO-2004101505-A1 | NOVEL COMPOUNDS FOR TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128662-A1 | Novel compounds for treatment of obesity | GPR119, FABP4, HSD17B4 | KAT6A 1539/4885HDAC3 212/4885HDAC4 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.